問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Veterans General Hosptial

  • 0

    Total Beds

  • 0

    Total Doctors

  • 807Kaohsiung CityKaohsiung Sanmin

Recruiting Trial

116Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

369Cases

2026-01-02 - 2029-09-30

Phase III

Not yet recruiting
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction

  • Condition/Disease

    Pulmonary Hypertension Associated With HFpEF

  • Test Drug

    Levosimendan

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2026-02-28 - 2031-02-21

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

  • Condition/Disease

    Lupus Erythematosus, Systemic

  • Test Drug

    JNJ-80202135 (Nipocalimab)

Participate Sites
6Sites

Recruiting6Sites

2024-07-01 - 2026-04-20

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2024-08-15 - 2026-12-31

Others

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

  • Condition/Disease

    High-risk Muscle Invasive Urothelial Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑

Participate Sites
6Sites

Not yet recruiting1Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
12Sites

Not yet recruiting1Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
10Sites

Not yet recruiting1Sites

2024-11-01 - 2028-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2024-12-01 - 2025-11-04

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2024-12-01 - 2027-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4 5 37
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB